down arrow

Bausch + Lomb Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA0717051076
USD
16.81
-0.15 (-0.88%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

16.8017.15

52 Week

10.4520.71
Valuation
Technical
Day's Volume

CASH

68.07 k

Shareholding (Mar 2025)

FII

4.23%

Held by 58 FIIs

DII

93.09%

Held by 8 DIIs

Promoter

1.38%

How big is Bausch + Lomb Corp.?

22-Jun-2025

As of Jun 18, Bausch + Lomb Corp. has a market capitalization of $4.09 billion, with recent net sales of $4.83 billion and a net profit of -$353 million.

Market Cap: As of Jun 18, Bausch + Lomb Corp. has a market capitalization of 4,092.33 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Bausch + Lomb Corp. reported net sales of 4,829.00 million and a net profit of -353.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 6,473.00 million and total assets of 13,469.00 million.

Read More

What does Bausch + Lomb Corp. do?

22-Jun-2025

Bausch + Lomb Corp. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1.137 billion and a net loss of $211 million as of March 2025. Key metrics include a market cap of $4.09 billion, a debt-to-equity ratio of 0.73, and a return on equity of -3.98%.

Overview:<BR>Bausch + Lomb Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,137 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -211 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 4,092.33 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.73 <BR>Return on Equity: -3.98% <BR>Price to Book: 0.64 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is Bausch + Lomb Corp. overvalued or undervalued?

20-Sep-2025

As of May 3, 2023, Bausch + Lomb Corp. is considered overvalued and risky due to its low Price to Book Value of 0.65, high EV to EBITDA ratio of 14.88, poor ROCE of 1.42%, and underperformance compared to the S&P 500, with a year-to-date return of -14.84%.

As of 3 May 2023, the valuation grade for Bausch + Lomb Corp. has moved from expensive to risky, indicating a shift in perception regarding its financial health and market position. The company appears to be overvalued, given its Price to Book Value of 0.65 and an EV to EBITDA ratio of 14.88, which suggests that investors are paying a premium despite the company's current losses. Additionally, the ROCE stands at a mere 1.42%, further highlighting the challenges the company faces in generating returns.<BR><BR>In comparison to its peers, Bausch + Lomb's valuation metrics are concerning; for instance, Penumbra, Inc. has a significantly higher P/E ratio of 75.41, while QIAGEN NV, which is considered fairly valued, has a more reasonable EV to EBITDA of 15.05. The company's recent stock performance has also lagged behind the S&P 500, with a year-to-date return of -14.84% compared to the index's gain of 12.22%. Overall, these factors suggest that Bausch + Lomb is currently overvalued in the market.

Read More

Is Bausch + Lomb Corp. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Bausch + Lomb Corp. shows a mildly bullish trend supported by the weekly MACD and daily moving averages, but caution is advised due to bearish monthly indicators and underperformance compared to the S&P 500.

As of 3 October 2025, the technical trend for Bausch + Lomb Corp. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, supporting the positive shift, while the daily moving averages also indicate a bullish stance. However, the monthly MACD and Bollinger Bands remain bearish, suggesting mixed signals across different time frames. The stock has underperformed the S&P 500 across all multi-period returns, with a year-to-date decline of 17.55% compared to the S&P 500's gain of 14.18%. Overall, the current technical stance is mildly bullish, but caution is warranted due to the bearish monthly indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROCE of 2.16%

  • The company has been able to generate a Return on Capital Employed (avg) of 2.16% signifying low profitability per unit of total capital (equity and debt)
2

The company declared negative results in Mar'25 after positive results in Dec'24

3

Risky -

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5,492 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.73

stock-summary
Return on Equity

-2.25%

stock-summary
Price to Book

0.85

Revenue and Profits:
Net Sales:
1,278 Million
(Quarterly Results - Jun 2025)
Net Profit:
-58 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.22%
0%
15.22%
6 Months
46.05%
0%
46.05%
1 Year
-14.84%
0%
-14.84%
2 Years
6.26%
0%
6.26%
3 Years
8.59%
0%
8.59%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Bausch + Lomb Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators

Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators

Bausch + Lomb Corp. has experienced a decline in stock value over the past year, underperforming the S&P 500. Technical indicators present a mixed outlook, with some suggesting short-term strength while others indicate a lack of definitive trends. The company faces ongoing challenges in a competitive market.

Read More

Is Bausch + Lomb Corp. technically bullish or bearish?

As of 3 October 2025, the technical trend for Bausch + Lomb Corp. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, supporting the positive shift, while the daily moving averages also indicate a bullish stance. However, the monthly MACD and Bollinger Bands remain bearish, suggesting mixed signals across different time frames. The stock has underperformed the S&P 500 across all multi-period returns, with a year-to-date decline of 17.55% compared to the S&P 500's gain of 14.18%. Overall, the current technical stance is mildly bullish, but caution is warranted due to the bearish monthly indicators....

Read More
Bausch + Lomb Forms Golden Cross, Signaling Potential Bullish Breakout Ahead

Bausch + Lomb Forms Golden Cross, Signaling Potential Bullish Breakout Ahead

Bausch + Lomb Corp. has recently experienced a Golden Cross, indicating a potential shift in momentum. While daily indicators show a bullish trend, mixed signals arise from the monthly MACD. The company has faced challenges over the past year, but recent trading suggests resilience amid fluctuating performance metrics.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
258.24%
EBIT Growth (5y)
133.59%
EBIT to Interest (avg)
-4.51
Debt to EBITDA (avg)
5.41
Net Debt to Equity (avg)
0.73
Sales to Capital Employed (avg)
0.40
Tax Ratio
8.95%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
18.83%
ROCE (avg)
2.16%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.65
EV to EBIT
56.08
EV to EBITDA
14.88
EV to Capital Employed
0.80
EV to Sales
1.81
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1.42%
ROE (Latest)
-3.98%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 24 Schemes (1.3%)

Foreign Institutions

Held by 58 Foreign Institutions (4.23%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 5.10% vs 17.49% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 60.81% vs -410.34% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,278.00",
          "val2": "1,216.00",
          "chgp": "5.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "118.00",
          "val2": "150.00",
          "chgp": "-21.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "131.00",
          "val2": "105.00",
          "chgp": "24.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-33.00",
          "val2": "-15.00",
          "chgp": "-120.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-58.00",
          "val2": "-148.00",
          "chgp": "60.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "8.60%",
          "val2": "32.90%",
          "chgp": "-2.43%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 15.56% vs 10.03% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -22.98% vs -1,753.33% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,791.00",
          "val2": "4,146.00",
          "chgp": "15.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "642.00",
          "val2": "586.00",
          "chgp": "9.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "412.00",
          "val2": "296.00",
          "chgp": "39.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-61.00",
          "val2": "-102.00",
          "chgp": "40.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-305.00",
          "val2": "-248.00",
          "chgp": "-22.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "43.00%",
          "val2": "49.20%",
          "chgp": "-0.62%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
1,278.00
1,216.00
5.10%
Operating Profit (PBDIT) excl Other Income
118.00
150.00
-21.33%
Interest
131.00
105.00
24.76%
Exceptional Items
-33.00
-15.00
-120.00%
Consolidate Net Profit
-58.00
-148.00
60.81%
Operating Profit Margin (Excl OI)
8.60%
32.90%
-2.43%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 5.10% vs 17.49% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 60.81% vs -410.34% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
4,791.00
4,146.00
15.56%
Operating Profit (PBDIT) excl Other Income
642.00
586.00
9.56%
Interest
412.00
296.00
39.19%
Exceptional Items
-61.00
-102.00
40.20%
Consolidate Net Profit
-305.00
-248.00
-22.98%
Operating Profit Margin (Excl OI)
43.00%
49.20%
-0.62%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 15.56% vs 10.03% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -22.98% vs -1,753.33% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Bausch + Lomb Corp. stock-summary
stock-summary
Bausch + Lomb Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."